Skip to main content
TipRanks
Go Ultimate75% OFF

Danaher (DHR) Recurring Revenue

3,338 Followers

Recurring Revenue

Measures the portion of revenue expected to continue in the future, indicating business stability and potential for sustained growth.

$0.00$1.00B$2.00B$3.00B$4.00B$5.00B$6.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Recurring revenue has moved from a mid‑$4B base into a steadier ~$5B run rate with clear multi‑year growth and stronger momentum through 2025–H1‑2026; however, quarter‑to‑quarter spikes and the pronounced year‑end troughs reflect timing/seasonality (respiratory testing swings) and bioprocessing shipment timing rather than a loss of underlying demand. Management’s M&A (Masimo closed, StatLab pending) and strong FCF support durable recurring mix expansion and buybacks, but expect lumpy quarterly cadence even as core recurring growth remains intact.

DHR Recurring Revenue

DateRecurring Revenue
Sep 30, 2026$5.40B
Jun 30, 2026$5.20B
Mar 31, 2026$5.03B
Dec 31, 2025$5.32B
Sep 30, 2025$5.02B
Jun 30, 2025$4.97B
Mar 31, 2025$4.82B
Dec 31, 2024$5.11B
Sep 30, 2024$4.78B
Jun 30, 2024$4.69B
Mar 31, 2024$4.79B
Dec 31, 2023$2.78B
Sep 30, 2023$5.18B
Jun 30, 2023$5.34B
Mar 31, 2023$5.39B
Dec 31, 2022$3.26B
Sep 30, 2022$5.83B
Jun 30, 2022$5.89B
Mar 31, 2022$5.90B
Dec 31, 2021$5.98B
Sep 30, 2021$5.42B
Jun 30, 2021$5.32B
Mar 31, 2021$5.08B
Dec 31, 2020$4.73B
Sep 30, 2020$4.23B
Jun 30, 2020$3.81B
Mar 31, 2020$3.21B
Dec 31, 2019$1.74B
Sep 30, 2019$3.50B
Jun 30, 2019$3.61B
Mar 31, 2019$3.46B
Dec 31, 2018$1.52B
Sep 30, 2018$3.35B
Jun 30, 2018$3.49B
Mar 31, 2018$3.32B